Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADD-VANTAGE: Pelacarsen with Background Inclisiran in ASCVD
NCT06813911Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2025
- Primary completion
- Feb 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic cardiovascular disease (ASCVD) comparing Pelacarsen with Placebo (2 arms). Primary endpoint: Change in log transformed lipoprotein A (Lp(a)) concentration at 6 months. Started Apr 2025; status: active, not recruiting.
02
Drugs
pelacarsen
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT06813911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06813911.